Vitamin D Deficiency and Connective Tissue Disease

Vitamins and Hormones

Volumn 86, Issue , 2011, Pages 261-286

  Zold, Eva ^a   Barta, Zsolt ^a   Bodolay, Edit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Autoimmune; Connective tissue diseases; Regulatory T cells; Vitamin D

Indexed keywords

VITAMIN D;

ANIMAL; AUTOIMMUNE DISEASE; BOOK; CONNECTIVE TISSUE DISEASE; HUMAN; IMMUNITY; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VITAMIN D DEFICIENCY;

ANIMALS; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; HUMANS; IMMUNITY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79952645855     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386960-9.00011-3     Document Type: Book

References (131)

1. Abbasi M., Rezaieyazdi Z., Afshari J.T., Hatef M., Sahebari M., Saadati N. Lack of association of vitamin D receptor gene BsmI polymorphisms in patients with systemic lupus erythematosus. Rheumatol. Int. 2010, 30:1537-1539.
2. Abe J., Nakamura K., Takita Y., Nakano T., Irie H., Nishii Y. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha, 25-dihydroxyvitamin D3. J. Nutr. Sci. Vitaminol. Tokyo 1990, 36:21-31.
3. Abraham D., Dashwood M. Endothelin-Role in vascular disease. Rheumatology (Oxford) 2008, 47(Suppl. 5):v23-v24.
4. Abraham D., Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res. Ther. 2007, 9(Suppl. 2):S2.
5. Adams J.S., Sharma O.P., Gacad M.A., Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 1983, 72:1856-1860.
6. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. NY Acad. Sci. 2003, 987:258-261.
7. Aguado P., del Campo M.T., Garces M.V., Gonzalez-Casaus M.L., Bernad M., Gijon-Banos J., et al. Low vitamin D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: Their relationship with bone mineral density. Osteoporos. Int. 2000, 11:739-744.
8. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1999, 17:453-456.
9. Artaza J.N., Norris K.C. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J. Endocrinol. 2009, 200:207-221.
10. Baeke F., Etten E.V., Overbergh L., Mathieu C. Vitamin D3 and the immune system: Maintaining the balance in health and disease. Nutr. Res. Rev. 2007, 20:106-118.
11. Bang B., Asmussen K., Sorensen O.H., Oxholm P. Reduced 25-hydroxyvitamin D levels in primary Sjogren's syndrome. Correlations to disease manifestations. Scand. J. Rheumatol. 1999, 28:180-183.
12. Becker A., Fischer R., Schneider M. Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus. Z. Rheumatol. 2001, 60:352-358.
13. Berer A., Stockl J., Majdic O., Wagner T., Kollars M., Lechner K., et al. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp. Hematol. 2000, 28:575-583.
14. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
15. Bettelli E., Korn T., Kuchroo V.K. Th17: The third member of the effector T cell trilogy. Curr. Opin. Immunol. 2007, 19:652-657.
16. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84:18-28.
17. Bodolay E., Csiki Z., Szekanecz Z., Ben T., Kiss E., Zeher M., et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin. Exp. Rheumatol. 2003, 21:313-320.
18. Borba V.Z., Vieira J.G., Kasamatsu T., Radominski S.C., Sato E.I., Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. 2009, 20:427-433.
19. Braun-Moscovici Y., Toledano K., Markovits D., Rozin A., Nahir A.M., Balbir-Gurman A. Vitamin D level: Is it related to disease activity in inflammatory joint disease?. Rheumatol. Int. 2009.
20. Broe K.E., Chen T.C., Weinberg J., Bischoff-Ferrari H.A., Holick M.F., Kiel D.P. A higher dose of vitamin d reduces the risk of falls in nursing home residents: A randomized, multiple-dose study. J. Am. Geriatr. Soc. 2007, 55:234-239.
21. Brown S.J. The role of vitamin D in multiple sclerosis. Ann. Pharmacother. 2006, 40:1158-1161.
22. Calzolari G., Data V., Carignola R., Angeli A. Hypovitaminosis D in systemic sclerosis. J. Rheumatol. 2009, 2844:36.
23. Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F. 1, 25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 1998, 160:5314-5319.
24. Caramaschi P., Dalla G.A., Ruzzenente O., Volpe A., Ravagnani V., Tinazzi I., et al. Very low levels of vitamin D in systemic sclerosis patients. Clin. Rheumatol. 2010, 29:1419-1425.
25. Carvalho J.F., Blank M., Kiss E., Tarr T., Amital H., Shoenfeld Y. Anti-vitamin D, vitamin D in SLE: Preliminary results. Ann. NY Acad. Sci. 2007, 1109:550-557.
26. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 1997, 7:439-443.
27. Chen Z., O'Shea J.J. Th17 cells: A new fate for differentiating helper T cells. Immunol. Res. 2008, 41:87-102.
28. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
29. Costenbader K.H., Feskanich D., Holmes M., Karlson E.W., Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 2008, 67:530-535.
30. Cutillas-Marco E., Morales-Suarez-Varela M., Marquina-Vila A., Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010, 19:810-814.
31. Cutolo M., Otsa K., Laas K., Yprus M., Lehtme R., Secchi M.E., et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 2006, 24:702-704.
32. Cutolo M., Otsa K., Paolino S., Yprus M., Veldi T., Seriolo B. Vitamin D involvement in rheumatoid arthritis and systemic lupus erythaematosus. Ann. Rheum. Dis. 2009, 68:446-447.
33. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 2008, 324:23-33.
34. DeLuca H.F. The vitamin D story: A collaborative effort of basic science and clinical medicine. FASEB J. 1988, 2:224-236.
35. DeLuca H.F., Cantorna M.T. Vitamin D: Its role and uses in immunology. FASEB J. 2001, 15:2579-2585.
36. DeLuca H.F., Zierold C. Mechanisms and functions of vitamin D. Nutr. Rev. 1998, 56:S4-S10.
37. Dimeloe S., Nanzer A., Ryanna K., Hawrylowicz C. Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and Vitamin D. J. Steroid Biochem. Mol. Biol. 2010, 120:86-95.
38. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal. Physiol. 2005, 289:F8-F28.
39. Feser M., Derber L.A., Deane K.D., Lezotte D.C., Weisman M.H., Buckner J.H., et al. Plasma 25, OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA. J. Rheumatol. 2009, 36:943-946.
40. Fritsche J., Mondal K., Ehrnsperger A., Andreesen R., Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003, 102:3314-3316.
41. Garcia-Lozano J.R., Gonzalez-Escribano M.F., Valenzuela A., Garcia A., Nunez-Roldan A. Association of vitamin D receptor genotypes with early onset rheumatoid arthritis. Eur. J. Immunogenet. 2001, 28:89-93.
42. Gauzzi M.C., Purificato C., Donato K., Jin Y., Wang L., Daniel K.C., et al. Suppressive effect of 1alpha, 25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: Impairment of functional activities and chemotaxis. J. Immunol. 2005, 174:270-276.
43. Gomez-Vaquero C., Fiter J., Enjuanes A., Nogues X., Diez-Perez A., Nolla J.M. Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. J. Rheumatol. 2007, 34:1823-1826.
44. Gourh P., Arnett F.C., Assassi S., Tan F.K., Huang M., Diekman L., et al. Plasma cytokine profiles in systemic sclerosis: Associations with autoantibody subsets and clinical manifestations. Arthritis Res. Ther. 2009, 11:R147.
45. Gregori S., Casorati M., Amuchastegui S., Smiroldo S., Davalli A.M., Adorini L. Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 2001, 167:1945-1953.
46. Holick M.F. McCollum Award Lecture, 1994: Vitamin D-New horizons for the 21st century. Am. J. Clin. Nutr. 1994, 60:619-630.
47. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80:1678S-1688S.
48. Holick M.F. Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 2004, 79:362-371.
49. Holick M.F. 25-OH-vitamin D assays. J. Clin. Endocrinol. Metab. 2005, 90:3128-3129.
50. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 2006, 81:353-373.
51. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
52. Holick M.F., Chen T.C. Vitamin D deficiency: A worldwide problem with health consequences. Am. J. Clin. Nutr. 2008, 87:1080S-1086S.
53. Huang C.M., Wu M.C., Wu J.Y., Tsai F.J. No association of vitamin D receptor gene start codon fok 1 polymorphisms in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 2002, 29:1211-1213.
54. Huang C.M., Wu M.C., Wu J.Y., Tsai F.J. Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus 2002, 11:31-34.
55. Huisman A.M., White K.P., Algra A., Harth M., Vieth R., Jacobs J.W., et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 2001, 28:2535-2539.
56. Hypponen E., Boucher B.J., Berry D.J., Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008, 57:298-305.
57. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N. Engl. J. Med. 2007, 357:2153-2165.
58. Jackson C., Gaugris S., Sen S.S., Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: A meta-analysis. QJM 2007, 100:185-192.
59. Jorgensen K.T., Wiik A., Pedersen M., Hedegaard C.J., Vestergaard B.F., Gislefoss R.E., et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: Case-control study nested in a cohort of Norwegian blood donors. Ann. Rheum. Dis. 2008, 67:860-866.
60. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 2006, 5:114-117.
61. Klareskog L., Alfredsson L., Rantapaa-Dahlqvist S., Berglin E., Stolt P., Padyukov L. What precedes development of rheumatoid arthritis?. Ann. Rheum. Dis. 2004, 63(Suppl. 2):ii28-ii31.
62. Klein R.G., Arnaud S.B., Gallagher J.C., DeLuca H.F., Riggs B.L. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J. Clin. Invest. 1977, 60:253-259.
63. Koizumi T., Nakao Y., Matsui T., Nakagawa T., Matsuda S., Komoriya K., et al. Effects of corticosteroid and 1, 24R-dihydroxy-vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP-lpr/lpr mice. Int. Arch. Allergy Appl. Immunol. 1985, 77:396-404.
64. Koren R., Ravid A., Rotem C., Shohami E., Liberman U.A., Novogrodsky A. 1, 25-Dihydroxyvitamin D3 enhances prostaglandin E2 production by monocytes. A mechanism which partially accounts for the antiproliferative effect of 1, 25(OH)2D3 on lymphocytes. FEBS Lett. 1986, 205:113-116.
65. Kroger H., Penttila I.M., Alhava E.M. Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand. J. Rheumatol. 1993, 22:172-177.
66. Kuruto-Niwa R., Nakamura M., Takeishi K., Nozawa R. Transcriptional regulation by C/EBP alpha and -beta in the expression of the gene for the MRP14 myeloid calcium binding protein. Cell Struct. Funct. 1998, 23:109-118.
67. Lange U., Teichmann J., Strunk J., Muller-Ladner U., Schmidt K.L. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos. Int. 2005, 16:1999-2004.
68. Lee C., Almagor O., Dunlop D.D., Chadha A.B., Manzi S., Spies S., et al. Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum. 2007, 57:585-592.
69. Lemire J.M. Immunomodulatory actions of 1, 25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 1995, 53:599-602.
70. Lemire J.M., Adams J.S., Sakai R., Jordan S.C. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest. 1984, 74:657-661.
71. Lemire J.M., Ince A., Takashima M. 1, 25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148.
72. Lim W.C., Hanauer S.B., Li Y.C. Mechanisms of disease: Vitamin D and inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2:308-315.
73. Linker-Israeli M., Elstner E., Klinenberg J.R., Wallace D.J., Koeffler H.P. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin. Immunol. 2001, 99:82-93.
74. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
75. Lodder M.C., Haugeberg G., Lems W.F., Uhlig T., Orstavik R.E., Kostense P.J., et al. Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: The Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum. 2003, 49:209-215.
76. Maalej A., Petit-Teixeira E., Michou L., Rebai A., Cornelis F., Ayadi H. Association study of VDR gene with rheumatoid arthritis in the French population. Genes Immun. 2005, 6:707-711.
77. Mahon B.D., Wittke A., Weaver V., Cantorna M.T. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell. Biochem. 2003, 89:922-932.
78. Malabanan A., Veronikis I.E., Holick M.F. Redefining vitamin D insufficiency. Lancet 1998, 351:805-806.
79. Martineau A.R., Wilkinson K.A., Newton S.M., Floto R.A., Norman A.W., Skolimowska K., et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin LL-37. J. Immunol. 2007, 178:7190-7198.
80. Masuda S., Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther. 2006, 5:797-808.
81. Matsuoka L.Y., Wortsman J., Dannenberg M.J., Hollis B.W., Lu Z., Holick M.F. Clothing prevents ultraviolet-B radiation-dependent photosynthesis of vitamin D3. J. Clin. Endocrinol. Metab. 1992, 75:1099-1103.
82. Matucci-Cerinic M., Seibold J.R. Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford) 2008, 47(Suppl. 5):v46-v47.
83. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7:429-442.
84. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis Rheum. 2004, 50:72-77.
85. Mitchell R.J., Fabb S.A., Whittingham S. Serum protein polymorphisms in patients with primary Sjogren's syndrome. Hum. Hered. 1985, 35:302-305.
86. Mosca M., Tavoni A., Neri R., Bencivelli W., Bombardieri S. Undifferentiated connective tissue diseases: The clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 1998, 7:95-100.
87. Mosca M., Tani C., Bombardieri S. Undifferentiated connective tissue diseases (UCTD): A new frontier for rheumatology. Best Pract. Res. Clin. Rheumatol. 2007, 21:1011-1023.
88. Mosser D.M., Zhang X. Interleukin-10: New perspectives on an old cytokine. Immunol. Rev. 2008, 226:205-218.
89. Muller K., Oxholm P., Sorensen O.H., Thymann M., Hoier-Madsen M., Bendtzen K. Abnormal vitamin D3 metabolism in patients with primary Sjogren's syndrome. Ann. Rheum. Dis. 1990, 49:682-684.
90. Muller K., Kriegbaum N.J., Baslund B., Sorensen O.H., Thymann M., Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 1995, 14:397-400.
91. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 2005, 26:662-687.
92. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003, 171:6173-6177.
93. Nielen M.M., Van S.D., Lems W.F., van de Stadt R.J., de Koning M.H., Reesink H.W., et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: Comment on the article by Merlino et al. Arthritis Rheum 2006, 54:3719-3720.
94. O'Regan S., Chesney R.W., Hamstra A., Eisman J.A., O'Gorman A.M., DeLuca H.F. Reduced serum 1, 25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr. Scand. 1979, 68:109-111.
95. Oberg F., Botling J., Nilsson K. Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J. Immunol. 1993, 150:3487-3495.
96. Oelzner P., Muller A., Deschner F., Huller M., Abendroth K., Hein G., et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif. Tissue Int. 1998, 62:193-198.
97. Orbach H., Zandman-Goddard G., Amital H., Barak V., Szekanecz Z., Szucs G., et al. Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. NY Acad. Sci. 2007, 1109:385-400.
98. Ozaki Y., Nomura S., Nagahama M., Yoshimura C., Kagawa H., Fukuhara S. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron 2000, 85:86-91.
99. Patel S., Farragher T., Berry J., Bunn D., Silman A., Symmons D. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007, 56:2143-2149.
100. Pedersen A.W., Holmstrom K., Jensen S.S., Fuchs D., Rasmussen S., Kvistborg P., et al. Phenotypic and functional markers for 1alpha, 25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin. Exp. Immunol. 2009, 157:48-59.
101. Penna G., Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
102. Penna G., Roncari A., Amuchastegui S., Daniel K.C., Berti E., Colonna M., et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 2005, 106:3490-3497.
103. Przybelski R.J., Binkley N.C. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch. Biochem. Biophys. 2007, 460:202-205.
104. Ramirez A.M., Wongtrakool C., Welch T., Steinmeyer A., Zugel U., Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J. Steroid Biochem. Mol. Biol. 2010, 118:142-150.
105. Rass P., Pakozdi A., Lakatos P., Zilahi E., Sipka S., Szegedi G., et al. Vitamin D receptor gene polymorphism in rheumatoid arthritis and associated osteoporosis. Rheumatol. Int. 2006, 26:964-971.
106. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 2005, 7:R784-R795.
107. Ross T.K., Darwish H.M., DeLuca H.F. Molecular biology of vitamin D action. Vitam. Horm. 1994, 49:281-326.
108. Rucker D., Allan J.A., Fick G.H., Hanley D.A. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002, 166:1517-1524.
109. Ruiz-Irastorza G., Egurbide M.V., Olivares N., Martinez-Berriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: Prevalence, predictors and clinical consequences. Rheumatol (Oxford) 2008, 47:920-923.
110. Sadeghi K., Wessner B., Laggner U., Ploder M., Tamandl D., Friedl J., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006, 36:361-370.
111. Sakulpipatsin W., Verasertniyom O., Nantiruj K., Totemchokchyakarn K., Lertsrisatit P., Janwityanujit S. Vitamin D receptor gene BsmI polymorphisms in Thai patients with systemic lupus erythematosus. Arthritis Res. Ther. 2006, 8:R48.
112. Scherberich J.E., Kellermeyer M., Ried C., Hartinger A. 1-alpha-calcidol modulates major human monocyte antigens and toll-like receptors TLR 2 and TLR4 in vitro. Eur. J. Med. Res. 2005, 10:179-182.
113. Schwalfenberg G. Not enough vitamin D: Health consequences for Canadians. Can. Fam. Physician 2007, 53:841-854.
114. Staeva-Vieira T.P., Freedman L.P. 1, 25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J. Immunol. 2002, 168:1181-1189.
115. Steingrimsdottir L., Gunnarsson O., Indridason O.S., Franzson L., Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 2005, 294:2336-2341.
116. Swamy N., Ray R. Affinity labeling of rat serum vitamin D binding protein. Arch. Biochem. Biophys. 1996, 333:139-144.
117. Szodoray P., Nakken B., Barath S., Gaal J., Aleksza M., Zeher M., et al. Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int. Immunol. 2008, 20:971-979.
118. Tetlow L.C., Smith S.J., Mawer E.B., Woolley D.E. Vitamin D receptors in the rheumatoid lesion: Expression by chondrocytes, macrophages, and synoviocytes. Ann. Rheum. Dis. 1999, 58:118-121.
119. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., et al. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 1998, 338:777-783.
120. Uitterlinden A.G., Fang Y., van Meurs J.B., Pols H.A., Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
121. Vacca A., Cormier C., Piras M., Mathieu A., Kahan A., Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J. Rheumatol. 2009, 36:1924-1929.
122. Vaisberg M.W., Kaneno R., Franco M.F., Mendes N.F. Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J. Clin. Lab. Anal. 2000, 14:91-96.
123. van Halteren A.G., van E.E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 2002, 51:2119-2125.
124. Vieth R., Cole D.E., Hawker G.A., Trang H.M., Rubin L.A. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur. J. Clin. Nutr. 2001, 55:1091-1097.
125. Wang T.T., Nestel F.P., Bourdeau V., Nagai Y., Wang Q., Liao J., et al. Cutting edge: 1, 25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173:2909-2912.
126. Welsh J., Wietzke J.A., Zinser G.M., Smyczek S., Romu S., Tribble E., et al. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 83:85-92.
127. Wright T.B., Shults J., Leonard M.B., Zemel B.S., Burnham J.M. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J. Pediatr. 2009, 155:260-265.
128. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1, 25-dihydroxyvitamin D(3). J. Cyst. Fibros. 2007, 6:403-410.
129. Zhu J., Paul W.E. CD4 T cells: Fates, functions, and faults. Blood 2008, 112:1557-1569.
130. Zold E., Szodoray P., Gaal J., Kappelmayer J., Csathy L., Gyimesi E., et al. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res. Ther. 2008, 10:R123.
131. Zold E., Szodoray P., Kappelmayer J., Gaal J., Csathy L., Barath S., et al. Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. Scand. J. Rheumatol. 2010, 39:490-497.